2013-P: A New Decision Aid Tool for Type 2 Diabetes (T2D): Design and Multistakeholder Usability Testing

Introduction and Objective: Glucose-lowering drugs for T2D have variable efficacy, side effect, and administration profiles. Tools that support individualized evidence-based prescribing in primary care are needed. Methods: We developed a decision aid (Figure) to support conversations about choice of T2D therapy, which we evaluated for usability, utility, and implementation in semi-structured interviews with 3 patients with T2D, 5 primary care providers (PCPs), and 3 endocrinologists. Results: The decision aid was well received by all stakeholders. Qualitative findings identified 5 themes to support implementation and use in practice (Table). Conclusion: This decision aid, available publicly, can support evidence-based individualized decisions about T2D drugs. Impacts on therapeutic inertia, guideline-concordant care, T2D outcomes, and satisfaction will need to be assessed. Disclosure A. Hawkins: None. A. Singh: None. U.F. Naeem: None. S. Khalid: None. I.G. Hargraves: None. K. Shepel: None. V. Montori: None. V.M. Montori: None. J.P. Brito: None. M.M. Mickelson: None. R. McCoy: None. Funding Patient-Centered Outcomes Research Institute (PCORI) Award (DB-2020C2-20306)